Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 11, 2009

Persistent Upgrades LIMS Application to Include Tissue Data for UC-Davis

  • Persistent Systems has partnered with the University of California, Davis to develop a data-management system for preclinical scientists. The tool called caELMIR 2 (electronic laboratory management information resource) will be based on the company’s caBIG® LIMS application.

    The updated version of caELMIR is integrated with caTissue, caBIG’s tissue-bank repository tool, for biospecimen inventory, tracking, and basic annotation. This caELMIR-caTissue integration reportedly enables scientists to store and access both preclinical data and tissue repository data, allowing them to find and procure tissues from previous experiments.

    Traditionally scientists have had to use specially designed databases to store the various data sets. The database was ineffective, however, when data collected did not fit in it. Additionally, such silo systems had synchronization issues, creating incomprehensible data.

    caELMIR 2 reportedly helps address these issues. It allows investigators to manage every aspect of preclinical studies, including tracking experimental tissue data and utilization, managing experiments, and handling the multitude of data types recorded for given experiments.

    The integration fully re-uses existing common data elements (CDE), ensuring semantic interoperability and retaining existing metadata information of all re-used CDEs to ensure seamless data exchange over the caGrid.


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »